Physician profile
Mark A Chastain
NPI 1790756138
$7,519.48
in general payments reported to CMS, 2019-2025
22 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $99.29 · 2021: $1,627 · 2022: $1,284 · 2023: $1,731 · 2024: $1,351 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,847 · Food and Beverage: $1,274 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,846.70 |
| Food and Beverage | $1,273.58 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,148.33 | 2019-2025 | Rinvoq |
| Allergan, INC. | $3,071.48 | 2019-2023 | |
| Genzyme Corporation | $263.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $150.18 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $128.92 | 2023-2025 | |
| Ucb, INC. | $116.59 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $87.37 | 2019-2024 | |
| Merz North America, INC. | $71.81 | 2022 | |
| Sun Pharmaceutical Industries INC. | $67.09 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $59.74 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.18 | 2023-2025 | Spevigo |
| Incyte Corporation | $41.55 | 2023-2024 | Opzelura |
| Dermavant Sciences, INC. | $40.84 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.89 | 2020-2025 | Jublia |
| Galderma Laboratories, L.P. | $35.85 | 2024-2025 | Nemluvio, Aklief |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $35.29 | 2025 | |
| Leo Pharma INC. | $26.61 | 2024 | Adbry |
| Janssen Biotech, INC. | $19.26 | 2025 | Tremfya |
| Dermira, INC. | $19.21 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.58 | 2019 | |
| Lilly USA, LLC | $14.87 | 2025 | Ebglyss, Taltz |
| Genentech USA, INC. | $12.91 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chastain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.